Premium
Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant
Author(s) -
Krolick M. A.
Publication year - 2005
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2005.01103.x
Subject(s) - bivalirudin , medicine , conventional pci , percutaneous coronary intervention , haemophilia , coronary artery disease , anticoagulant , heparin , intervention (counseling) , surgery , cardiology , myocardial infarction , nursing
Summary. This article presents the case of a patient with severe haemophilia A who underwent successful multivessel percutaneous coronary intervention (PCI). Patients with haemophilia who are diagnosed with coronary artery disease (CAD) and require intervention present a challenge to doctors due to the high risks of bleeding. The patient was administered recombinant factor VIII pre‐ and post‐procedure. Anticoagulation during PCI was maintained with bivalirudin, a thrombin‐specific anticoagulant. There were no complications and the patient tolerated the procedure well. This case suggests that bivalirudin as the sole procedural anticoagulant can be safely used in patients with a very high risk of bleeding undergoing PCI.